Lilly's Orforglipron Excels in Phase 3 Trials for Type 2 Diabetes
TL;DR Summary
Eli Lilly's oral GLP-1 receptor agonist, orforglipron, showed superior glycemic control in two Phase 3 trials, outperforming dapagliflozin and oral semaglutide, with significant A1C reductions and weight loss, supporting its potential as a new standard treatment for type 2 diabetes.
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
8 min
vs 9 min read
Condensed
98%
1,634 → 40 words
Want the full story? Read the original article
Read on investor.lilly.com